Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 6/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12313691 | 0.85 | CCR2 (0.40) | CCR2KCNH2HRH3DRD3KDM4E | |
| SCHEMBL12313698 | 0.83 | CCR2 (0.42) | CCR2KCNH2HRH3DRD3KDM4E | |
| SCHEMBL18531912 | 0.83 | CCR2 (0.40) | CCR2KCNH2HRH3CYP1A2CYP2D6 | |
| SCHEMBL12413985 | 0.82 | ALDH1A1 (0.42) | CYP1A2CYP2D6CYP2C9CYP2C19DRD3 | |
| SCHEMBL4192102 | 0.81 | ALDH1A1 (0.39) | CYP1A2CYP2D6CYP2C9CYP2C19DRD3 | |
| SCHEMBL12313383 | 0.81 | KDM4E (0.41) | CCR2KCNH2HRH3CYP2C19DRD3 | |
| SCHEMBL20179875 | 0.80 | CCR2 (0.38) | CCR2KCNH2HRH3CYP1A2CYP2D6 | |
| SCHEMBL23276967 | 0.79 | CYP1A2 (0.41) | HRH3CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4550200 | 0.79 | CYP1A2 (0.41) | HRH3CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL24530509 | 0.79 | CCR2 (0.39) | CCR2KCNH2HRH3DRD3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921515-B2 | Methods and compositions of preparation for proteome analysis | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130172539-A1 | METHODS AND COMPOSITIONS OF PREPARATION FOR PROTEOME ANALYSIS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130053371-A1 | INHIBITORS OF PI3 KINASE | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2013-02-28 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| WO-2010149684-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-29 | — | — | WO | disclosed |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| EP-0816381-B1 | POLYETHYLENE GLYCOL MODIFIED HEPATOCYTE GROWTH FACTOR (HGF) | NAKAMURA TOSHIKAZU (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-6380356-B1 | DIMERS WITH GIVEN LINKING GROUPS; USE AGAINST GRAM-NEGATIVE BACTERIAL INFECTIONS | ADVANCED MEDICINE, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-0989857-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| EP-0473084-A2 | Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-03-04 | — | — | EP | disclosed |
| US-5093531-A | POLYETHYLENE GLYCOL SUBSTITUTED PHENYL GLYOXALS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-03-03 | — | — | US | disclosed |
| EP-0458903-A1 | SOLUBLE ANALOGS OF THROMBOMODULIN | CODON (US) | 1991-12-04 | — | — | EP | disclosed |
| EP-0400486-A2 | Polyethylene glycol derivatives, modified peptides and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-12-05 | — | — | EP | disclosed |
| WO-1990010081-A1 | SOLUBLE ANALOGS OF THROMBOMODULIN | CODON (US) | 1990-09-07 | — | — | WO | disclosed |
| US-4913812-A | GLYCIDYL VINYL(ETHER OR ESTER)COPOLYMER BONDED TO LIGAND | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0340741-A2 | Polyethylene glycol derivatives, modified peptides and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-11-08 | — | — | EP | disclosed |
| EP-0333587-A2 | Method for purifying and isolating carboxyl-terminal peptides | MITSUBISHI KASEI CORPORATION (JP) | 1989-09-20 | — | — | EP | disclosed |
| US-4315074-A | RESIN PEPTIDES FOR SYNTHESIZING POLYPEPTIDES | PIERCE CHEMICAL COMPANY (US) | 1982-02-09 | — | — | US | disclosed |
| US-4182654-A | SOLID PHASE SYNTHESIS | PIERCE CHEMICAL COMPANY (US) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053371-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, MTOR, PIK3C2A | CCR2 4413/4885KCNH2 4269/4885HRH3 2045/4885 |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | CCR2 2976/4885KCNH2 4559/4885HRH3 3131/4885 |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | CCR2 3048/4885KCNH2 4852/4885HRH3 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.